Medication adherence to rivaroxaban and dabigatran in patients with non-valvular atrial fibrillation: a meta-analysis

被引:0
作者
Ashley Prentice
Irene Ruiz
Erin R. Weeda
机构
[1] Medical University of South Carolina,College of Pharmacy
来源
Journal of Thrombosis and Thrombolysis | 2020年 / 49卷
关键词
Medication adherence; Direct oral anticoagulant; Atrial fibrillation; Proportion of days covered;
D O I
暂无
中图分类号
学科分类号
摘要
Several real-world studies have evaluated adherence to direct acting oral anticoagulants in patients with non-valvular atrial fibrillation (NVAF); however, these studies have not been systematically summarized. We performed a meta-analysis to compare adherence to rivaroxaban versus dabigatran therapy in United States (US) patients with NVAF in a real-world setting. Medline and Scopus were searched from January 2010 to August 2018 using keywords and MeSH terms related to adherence and oral anticoagulants. We included real-world studies of US adults with NVAF comparing adherence to dabigatran and rivaroxaban. Studies evaluating adherence by a measure other than proportion of days covered (PDC) were excluded. The proportion of patients with a PDC ≥ 80 (a commonly utilized definition of adherence) served as the primary outcome of interest. We conducted meta-analysis of non-overlapping studies using the Hartung–Knapp random-effects model to estimate risk ratios (RRs) with corresponding 95% confidence intervals (CIs). We included 5 studies evaluating 80,230 patients (range 2667–22,571). Median follow-up across studies was 6 months (range 3–12 months). The proportion of patients with a PDC ≥ 80 ranged from 59.5 to 83.5% for rivaroxaban users and 57.3 to 78.3% for dabigatran users. Upon meta-analysis, rivaroxaban use was associated with increased adherence compared with dabigatran use (RR  1.08; 95% CI  1.03–1.12; I2 = 88%). In conclusion, rivaroxaban was associated with increased adherence when compared to dabigatran in ~ 80,000 patients in a real-world setting. Possible explanations for this include dosing frequency or patient tolerance.
引用
收藏
页码:360 / 364
页数:4
相关论文
共 47 条
[1]  
Reading SR(2019)Risk factors for medication non-adherence among atrial fibrillation patients BMC Cardiovasc Disord 19 38-992
[2]  
Black MH(2011)Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 981-1151
[3]  
Singer DE(2009)Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 1139-236
[4]  
Granger CB(2017)Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration BMC Cardiovasc Disord 17 236-2173
[5]  
Alexander JH(2016)Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation J Am Heart Assoc 5 e003074-988
[6]  
McMurray JJ(2015)Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure Curr Med Res Opin 31 2167-173
[7]  
Connolly SJ(2017)Adherence to rivaroxaban compared with other oral anticoagulant agents among patients with nonvalvular atrial fibrillation J Manag Care Spec Pharm 23 980-1113
[8]  
Ezekowitz MD(2016)Medication adherence to rivaroxaban and dabigatran for stroke prevention in patients with non-valvular atrial fibrillation in the United States Int J Cardiol 212 171-1705
[9]  
Yusuf S(2016)The GRACE checklist: a validated assessment tool for high quality observational studies of comparative effectiveness J Manag Care Spec Pharm 22 1107-144
[10]  
Borne RT(2015)Adherence to oral anticoagulant therapy in secondary stroke prevention—impact of the novel oral anticoagulants Patient Prefer Adher 9 1695-497